TY - JOUR
T1 - Pulse pressure and effects of Losartan or atenolol in patients with hypertension and left ventricular hypertrophy
AU - Fyhrquist, F
AU - Dahlof, B
AU - Devereux, RB
AU - Kjeldsen, K
AU - Julius, S
AU - Beevers, David
AU - de Faire, U
AU - Ibsen, H
AU - Kristianson, K
AU - Lederballe-Pedersen, O
AU - Lindholm, LH
AU - Nieminen, MS
AU - Onvik, P
AU - Oparil, S
AU - Hille, DA
AU - Lyle, PA
AU - Edelman, JM
AU - Snapinn, SM
AU - Wedel, H
PY - 2005/2/28
Y1 - 2005/2/28
N2 - In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy. The objective of this post hoc analysis was to determine the influence of pulse pressure on outcome. Patients were divided into quartiles of baseline pulse pressure. Cox regression, including baseline Framingham risk score as a covariate, was used to compare risk in the quartiles. In the atenolol group, there were significantly higher risks in the highest versus lowest quartile for the composite end point 28% (confidence interval [CI], 2% to 62%; P=0.035), stroke 84% (CI, 32% to 157%; P0.2), stroke -5% (CI, -34% to 37%; P>0.2), myocardial infarction 30% (CI, -13% to 94%; P>0.2), and total mortality 32% (CI, -1% to 76%; P=0.062). In patients with hypertension and left ventricular hypertrophy in the LIFE study, there were significantly higher risks, adjusted for the Framingham risk score, for the primary composite end point, stroke, and total mortality in the highest versus lowest quartile of pulse pressure with atenolol-based treatment. The risks in the losartan group also increased with increasing pulse pressure quartile, but were lower than those in the atenolol group, and were not significant.
AB - In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, the primary composite end point of cardiovascular death, stroke, and myocardial infarction was reduced by losartan versus atenolol in patients with hypertension and left ventricular hypertrophy. The objective of this post hoc analysis was to determine the influence of pulse pressure on outcome. Patients were divided into quartiles of baseline pulse pressure. Cox regression, including baseline Framingham risk score as a covariate, was used to compare risk in the quartiles. In the atenolol group, there were significantly higher risks in the highest versus lowest quartile for the composite end point 28% (confidence interval [CI], 2% to 62%; P=0.035), stroke 84% (CI, 32% to 157%; P0.2), stroke -5% (CI, -34% to 37%; P>0.2), myocardial infarction 30% (CI, -13% to 94%; P>0.2), and total mortality 32% (CI, -1% to 76%; P=0.062). In patients with hypertension and left ventricular hypertrophy in the LIFE study, there were significantly higher risks, adjusted for the Framingham risk score, for the primary composite end point, stroke, and total mortality in the highest versus lowest quartile of pulse pressure with atenolol-based treatment. The risks in the losartan group also increased with increasing pulse pressure quartile, but were lower than those in the atenolol group, and were not significant.
UR - http://www.scopus.com/inward/record.url?scp=20144386365&partnerID=8YFLogxK
U2 - 10.1161/01.HYP.0000161186.55933.6b
DO - 10.1161/01.HYP.0000161186.55933.6b
M3 - Article
C2 - 15790960
SN - 1524-4563
VL - 45
SP - 580
EP - 585
JO - Hypertension
JF - Hypertension
ER -